Baricitinib in Patients with Inadequate Response or Intolerance to Conventional Synthetic DMARDs: Results from the RA-BUILD Study
Ann Rheum Dis 2017;76:88–95.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis 2017;76:88–95.
J Rheumatol 2017;44:2. DOI 10.3899/jrheum.160287.
Ann Rheum Dis 2016. DOI 10.1136/annrheumdis-2016-210310
Arthritis & Rheum 2016; ePub ahead of print
Ann Rheum Dis 2016;75:1979–83
Arthritis Res Ther 2016; 18:211. DOI 10.1186/s13075-016-1108-9
Arthritis Care Res 2016; Accepted article. DOI 10.1002/acr.23008.
Arthritis Rheumatol 2016; Accepted article DOI 10.1002/art-39808 [Epub 2016]
Ann Rheum Dis 2016;0:1–7 DOI 10.1136/annrheumdis-2016-209773.
Drug Saf. 2016 June 9; 39:755–762; DOI 10.1007/s40264-016-0431-z [Epub ahead of print]